## **REMARKS**

Claims 1-17 are pending. Claims 2-7 and 10-17 are canceled without prejudice.

Claims 18-19 are added. Claims 1, 8, and 9 are amended. Support for the amendment to

Claim 1 is found in original Claim 1 and the Specification at page 18, lines 3-10 and page 20,

lines 1-12. Support for the amendment to Claim 8 is found in the Specification on page 4,

line 10 – page 5, line 28. Support for new Claims 18-19 is found on page 4, line 10 – page 5,

line 28 of the present Specification and original Claim 9. No new matter is believed to be

added upon entry of the amendment. Upon entry of the amendment, Claims 1-8-9, and 18-19

will be active.

The rejections of any one of Claims 1-17 under 35 U.S.C. § 102(b) over the disclosures of U.S. Patent Nos. 5,989,737 (hereafter US '737) and 6,203,933 (hereafter US '933) are respectfully traversed.

US '737 discloses an organic electroluminescent (EL) device that contains an organic hole injecting and transporting layers that contain a mixture of a tertiary aromatic amine and a polycyclic aromatic hydrocarbon compound (see Abstract and col. 3, lines 23-28).

US '737 discloses that the tertiary aromatic amine is represented by the formulae shown on col. 5, lines 5-56.

US '737 also discloses that the polycyclic aromatic hydrocarbon compound is disclosed in the illustrative examples of formulae (1)-(26) (see col. 6, line 7-col. 11, line 45).

Applicants note that the EL device of Claim 1 is unlike that disclosed in US '737 because US '737 does not disclose a layer of an organic light emitting medium that comprises an arylamine and a compound shown in formula (IV).

Applicants also note that the EL device of Claims 8 and 18 differ from that which is disclosed in US '737 does not disclose an arylamine as recited in formula (V) in combination with the component (B) specified in these claims.

Application No. 10/617,397

Reply to Office Action of February 9, 2005

US '933 discloses an organic EL element that contains an organic compound layer

containing a compound (Ar)<sub>m</sub>-L (see Abstract and col. 3, lines 11-26), wherein L is a divalent

or trivalent residue compound derived from anthracene. US '933 discloses representative

formulae for L beginning on col. 4, line 50 and ending on col. 11, line 10. US '933 also

discloses triarylamine substituents that are covalently attached to the Ar of (Ar)<sub>m</sub>-L (see the

 $R^5$  and  $R^{12}$  substituents shown in cols. 11-12, 13-14, 15-16, 17-18, etc.).

Applicants note that the compounds that are contained in the organic EL layers

disclosed in US '933 are unlike that which is recited in Claims 1, 8-9, and 18-19.

In view of the above-noted differences, it is kindly requested that the Examiner

withdraw these rejections.

The rejection of Claims 5-9 and 14 under 35 U.S.C. § 112, second paragraph is

believed to be obviated by amendment.

Claims 5-7 and 14 are canceled. Claim 9 is amended to include "X<sup>3</sup>" in formula (V).

In view of these amendments, it is kindly requested that the Examiner withdraw this

rejection.

Applicants note that statutory period for reply to the Office Action dated February 9,

2005 expires on August 9, 2005. Accordingly, Applicants file concurrently herewith a

request for a three-month extension of time under 37 CFR § 1.136, with the appropriate fee

under 37 CFR § 1.17. Should there exist a variance between that which is paid and owed, the

Office is authorized to charge deposit account number 15-0030, in order to maintain

pendency of the above-identified application.

Customer Number

22850

Tel: (703) 413-3000 Fax: (703) 413 -2220

(OSMMN 06/04)

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, P.C.

Norman F. Oblon

Daniel R. Evans, Ph.D.

Registration No. 55,868

10